Jackie Hunter: BenevolentBio

13 : 12 : 2016 Jackie Hunter : BenevolentBio : Artificial Intelligence

The way I look at it is that we have experienced scientists who are like chefs in a kitchen, and what AI does is give them a higher-quality set of ingredients to work with.

Jackie Hunter, CEO, BenevolentBio

The CEO of BenevolentBio, a company that uses artificial intelligence (AI) to boost the speed of medical research, explains how the technology is going to transform drug discovery and why businesses shouldn’t consider it a panacea.

What this means to your brands

1. Make the negative positive. Hunter points out that bad information can be as instructive for machine learning as good, so don’t restrict your AI’s diet.

2. Forget silver bullets. While Hunter is an AI evangelist, she reiterates that companies can’t treat the technology as a panacea and need to consider each business case.

3. Augment rather than replace. AI isn’t going to usurp a clinician, but rather help them do the same work more effectively.

4. Look at the long tail. While speeding up the drug discovery process is AI’s immediate benefit, the knock on efficiencies in doctor-patient care are just as valuable.

5. It’s not all about the science. Hunter believes AI’s ability to improve the social aspect of medical care via better human-machine interfaces will be transformative.